July 21, 2023 07:11 AM EDT

Codexis cuts 25% of staff, slashes drug programs while doubling down on RNAi tech

Amber Tong

The enzyme engineering specialists at Codexis are giving up on making their own therapies, instead focusing on selling its technologies and services to customers …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Codexis cuts 25% of staff, slashes drug programs while doubling down on RNAi tech

Amber Tong

Sign up to read this article for free.

A look at biotech's year of the megaround

After CagriSema, eyes are on Lilly’s oral GLP-1 as next key obesity play

Neumora's major depression drug flunks first of three Phase 3 trials

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Regeneron buys London-based ocular biotech

Roche circles back to China biotech with $80M deal for lung cancer ADC

Codex­is cuts 25% of staff, slash­es drug pro­grams while dou­bling down on RNAi tech

Amber Tong

Sign up to read this article for free.

more like this

A look at biotech's year of the megaround

Af­ter Ca­griSe­ma, eyes are on Lil­ly’s oral GLP-1 as next key obe­si­ty play

Neu­mora's ma­jor de­pres­sion drug flunks first of three Phase 3 tri­als

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Re­gen­eron buys Lon­don-based oc­u­lar biotech

Roche cir­cles back to Chi­na biotech with $80M deal for lung can­cer ADC

Codexis cuts 25% of staff, slashes drug programs while doubling down on RNAi tech

After CagriSema, eyes are on Lilly’s oral GLP-1 as next key obesity play

Neumora's major depression drug flunks first of three Phase 3 trials

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Regeneron buys London-based ocular biotech

Roche circles back to China biotech with $80M deal for lung cancer ADC